Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 22,242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Dry Eye Disease
Interventions: rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution); Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Dinesh Khanna, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more

Conditions: Healthy
Interventions: BFR, Stanard strengthening program.; Device · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia, Impulsive Behavior
Interventions: Nicotine Patch, 7 Mg/24 Hr, Placebo patch; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Lymphocytic Leukemia
Interventions: Questionnaires, Fit Bit; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated interferon alfa 2a; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more

Conditions: Inflammatory Bowel Diseases
Interventions: mucosal impedance (MI) testing; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV
Interventions: PRO 140, Placebo; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Patient Lying, Privacy Statements, Risk Statements, Benefit Statements, Patient Lie Detection
Interventions: Benefit statement, Risk Statement, Privacy Statement, Benefit + Privacy, Risk + Privacy; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 619 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Provo, Utah

Conditions: Steatohepatitis
Interventions: Placebo capsule, EPA-E 300 mg capsule; Drug
Lead sponsor: Mochida Pharmaceutical Company, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Dothan, Alabama • Tucson, Arizona • Anaheim, California + 27 more

Conditions: Obesity
Interventions: 24-hour energy expenditure and substrate utilization; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Sleep Disorders
Interventions: Nonpharmacological sleep intervention, Active control; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 60 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Sepulveda, California

Conditions: HIV Infections
Interventions: VGX-410 (Mifepristone), Placebo for VGX-410 (Mifepristone); Drug
Lead sponsor: VGX Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Smoking
Interventions: WebQuit study group, WebQuit control group; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 721 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dysphagia
Interventions: Treatment 1; Dexamethasone, Treatment 0; Saline placebo; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Shoulder Pain, Opioid Use
Interventions: Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chemotherapy-induced Peripheral Neuropathy, Taxane-Induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions: Paxman Limb Cryocompression System; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hernia, Inguinal
Interventions: ULTRAPRO Mesh, 3DMAX, Evaluation; Device · Other
Lead sponsor: South East Area Health Education Center, Wilmington, NC; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Severe Orthopedic Trauma
Interventions: Trauma Collaborative Care Plus Treatment as Usual; Behavioral
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 13
States / cities: Denver, Colorado • Tampa, Florida • Indianapolis, Indiana + 9 more

Conditions: Cirrhosis, Liver, End Stage Liver DIsease, Symptoms and Signs, Physical Inactivity, Muscle Loss
Interventions: LiverWatch Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Structured access to a Wii game computer (Wii), Motivational support only; Behavioral
Lead sponsor: Linkoeping University; Government
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Irvine, California

Conditions: Postoperative Pain
Interventions: pre-operative carbohydrate drink, Acetaminophen, Gabapentin, Bupivacaine, Ambulation; Dietary Supplement · Drug · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Healthy
Interventions: Canagliflozin (JNJ-28431754), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Diabetes Mellitus
Interventions: Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 12 more

Search by objective public record fields.

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

Lower Extremity BFR-randomized Controlled Trial Healthy Volunteers

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Assessment of Colonic Epithelial Integrity With Mucosal Impedance

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

Patient Doctor Lies

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

Impact of Black Pepper on Energy Expenditure and Substrate Utilization

Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation

Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

WebQuit Online Smoking Cessation Study

Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline

Multimodal Analgesia in Shoulder Arthroplasty

Cryocompression for CIPN

Prospective Trial Comparing Two Different Polypropylene Meshes for Inguinal Hernias

Improving Activity and Quality of Life Following Orthopaedic Trauma: The Trauma Collaborative Care Study (TCCS)

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

Increasing Exercise Capacity of Patients With Heart Failure by Wii Gaming

Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control